Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896337 · ClinicalTrials.gov registry record · Phase 3
EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT00896337 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 125 participants.
The verdict
NCT00896337, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
Interventions
- DEVICE Epic™ Nitinol Stent System
- DRUG Anti-platelet therapy
- DRUG Anti-coagulation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896337
The ClinicalTrials.gov registry entry for NCT00896337 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epic™ Nitinol Stent System is the first listed.
NCT00896337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896337 about?
NCT00896337 is a clinical study titled "EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries". The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
What is the current status of trial NCT00896337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2009-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00896337?
The interventions under investigation include: Epic™ Nitinol Stent System (DEVICE), Anti-platelet therapy (DRUG), Anti-coagulation therapy (DRUG).
Who is sponsoring clinical trial NCT00896337?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.